Symptomatic spleno-mesenteric-portal venous thrombosis: Recanalization andreconstruction with endovascular stents

PURPOSE: To evaluate the safety and efficacy of portal reconstruction in pa tients with symptomatic spleno-mesenteric-portal venous thrombosis. MATERIALS AND METHODS: Portal reconstruction was attempted in 21 patients ( seven women, 14 men; mean age, 53.6 years +/- 15.2) with chronic thrombosis of the portal vein alone (n = 8), splenic vein alone (n = 3), or portal, m esenteric, and splenic veins (n = 10). Indications for the procedure were b leeding varices (n = 15), ascites (n = 2), hypersplenism (rt = 2), and ente ropathy (n = 2). Sixteen procedures were started transhepatically and of th ese seven were converted to a transjugular intrahepatic portosystemic shunt (TIPS) after successful recanalization of the thrombosed vein. In six pati ents reconstructions were performed using an intrahepatic portal vein as ou tflow. Five procedures were performed primarily as TIPS. Wallstents dilated to 7-10 mm were used for reconstruction. The mean follow-up period was 15. 2 months +/- 15.9. RESULTS: Technical success of portal reconstruction was 85.7% (18 of 21). T hirty-day mortality was 14.3% (three of 21) but was not procedural related. The cumulative rates of survival, primary patency, and palliation at 43 mo nths of follow-up were 61.2% +/- 13.5%, 63.5% +/- 15.3%, and 31.7% +/- 15.7 %, respectively. Secondary patency was 79.1% +/- 13.8%. The only predictor of mortality was the presence of liver disease (P = .001, Cox regression). CONCLUSION: Portal reconstruction is a safe and effective treatment option for patients with symptomatic chronic portal thrombosis. Liver disease pred isposes to a higher mortality.